Gostyńska Aleksandra, Piwowarczyk Ludwika, Nadolna Malwina, Jelińska Anna, Dettlaff Katarzyna, Ogrodowczyk Magdalena, Popielarz-Brzezińska Maria, Stawny Maciej
Department and Chair of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka, 60-780 Poznań, Poland.
Antibiotics (Basel). 2021 Feb 22;10(2):217. doi: 10.3390/antibiotics10020217.
Simultaneous administration of parenteral nutrition (PN) admixtures with intravenous antibiotics is a common clinical problem. Coadministration of drugs incompatible with PN admixture may affect its stability, especially in the context of lipid droplet size, which is a crucial parameter for patient safety. In the present study, we investigate the in vitro compatibility of meropenem (Meropenem 1000, MPM) with five commercial PN admixtures used worldwide: Kabiven, Olimel N9E, Nutriflex Lipid Special, Nutriflex Omega Special, and SmofKabiven. The appropriate volumetric ratios, reflecting their clinical practice ratios, were used to prepare the MPM-PN admixture samples. Physicochemical properties of MPM-PN admixtures samples were determined upon preparation and after four hours of storage. The pH changes for all MPM-PN admixtures samples did not exceed the assumed level of acceptability and ranged from 6.41 to 7.42. After four hours of storage, the osmolarity changes were ±3%, except MPM-Olimel N9E samples, for which differences from 7% to 11% were observed. The adopted level of acceptability of changes in zeta potential after four hours of storage (±3 mV) was met for MPM-Kabiven, MPM-Nutriflex Lipid Special, and MPM-Nutriflex Omega Special. The mean droplet diameter for all samples was below 500 nm. However, only in the case of Nutriflex Lipid Special and Nutriflex Omega Special, the addition of MPM did not cause the formation of the second fraction of lipid droplets. The coadministration of MPM via Y-site with Kabiven, Olimel N9E, and Smofkabiven should be avoided due to osmolarity fluctuations (MPM-Olimel), significant differences in zeta potential (MPM-Olimel, MPM-Smofkabiven), and the presence of the second fraction of lipid droplets >1000 nm (MPM-Kabiven, MPM-Olimel, and MPM-Smofkabiven). The assumed acceptance criteria for MPM compatibility of MPM with PN admixtures were met only for Nutriflex Lipid Special and Nutriflex Omega Special in 1:1, 2:1, and 4:1 volume ratios.
肠外营养(PN)混合液与静脉用抗生素同时给药是一个常见的临床问题。与PN混合液不相容的药物共同给药可能会影响其稳定性,尤其是在脂滴大小方面,而脂滴大小是关乎患者安全的关键参数。在本研究中,我们研究了美罗培南(美罗培南1000,MPM)与全球使用的五种市售PN混合液的体外相容性:卡文(Kabiven)、奥力美N9E(Olimel N9E)、特殊营养脂质(Nutriflex Lipid Special)、特殊营养欧米伽(Nutriflex Omega Special)和卡文复合鱼油脂肪乳(SmofKabiven)。采用反映其临床应用比例的合适体积比来制备MPM - PN混合液样品。在制备后以及储存4小时后测定MPM - PN混合液样品的理化性质。所有MPM - PN混合液样品的pH变化均未超过假定的可接受水平,范围为6.41至7.42。储存4小时后,除了MPM - 奥力美N9E样品的渗透压变化为7%至11%外,其他样品的渗透压变化均为±3%。对于MPM - 卡文、MPM - 特殊营养脂质和MPM - 特殊营养欧米伽,储存4小时后ζ电位变化的假定可接受水平(±3 mV)得到满足。所有样品的平均液滴直径均低于500 nm。然而,仅在特殊营养脂质和特殊营养欧米伽的情况下,添加MPM不会导致形成第二部分脂滴。由于渗透压波动(MPM - 奥力美)、ζ电位存在显著差异(MPM - 奥力美、MPM - 卡文复合鱼油脂肪乳)以及存在大于1000 nm的第二部分脂滴(MPM - 卡文、MPM - 奥力美和MPM - 卡文复合鱼油脂肪乳),应避免通过Y型接口将MPM与卡文、奥力美N9E和卡文复合鱼油脂肪乳同时给药。仅特殊营养脂质和特殊营养欧米伽在1:1、2:1和4:1体积比下满足MPM与PN混合液相容性的假定接受标准。